The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Study Probes New Gene Therapy for Severe, Localized Scleroderma (Morphea)

Study Probes New Gene Therapy for Severe, Localized Scleroderma (Morphea)

August 16, 2019 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
A morphea plaque on the leg.

A morphea plaque on the leg.
Dr Harout Tanielian / Science Source

In September 2018, the U.S. Food & Drug Administration (FDA) granted fast-track status to FCX‑013, a gene therapy product developed to treat moderate to severe localized scleroderma (morphea). Previously, the treatment received an orphan drug designation for localized scleroderma, as well as a rare pediatric disease designation. Phase 1 and 2 studies will assess safety and suggest whether FCX-013 holds promise for this damaging disease, which currently lacks FDA-approved treatments.

You Might Also Like
  • Targeted Therapy for Scleroderma Fibrosis
  • A Deep-Dive Discussion with the Author of a Systemic Scleroderma Study
  • Studies Show Promise for Scleroderma Therapy and Prediction of Progressing Disease
Explore This Issue
August 2019
Also By This Author
  • Race As a Risk Factor for Sjögrens Syndrome

Systemic Sclerosis & Localized Scleroderma

The sclerotic disease, scleroderma, can be classified as two distinct autoimmune syndromes: systemic sclerosis and localized scleroderma. Although the latter is thought to only rarely progress to the former, the two share overlapping findings in histology, cell biology and pathophysiology. Systemic sclerosis is characterized by cutaneous sclerosis and deep visceral involvement, whereas localized scleroderma primarily causes skin symptoms. However, localized scleroderma encompasses a spectrum of different skin depths and patterns of lesions. In some subtypes, localized scleroderma may also affect nearby tissues, such as fat, fascia, muscle and bone.1,2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Some confusion exists over terminology, with many rheumatologists preferring the term morphea to localized scleroderma, partly due to concerns that patients may confuse localized scleroderma with systemic sclerosis. However, in some contexts, the term morphea is also used to refer to a specific subtype of localized scleroderma, plaque morphea, the most common subtype found in adults.1,2

David F. Fiorentino, MD, PhD, is a professor in the Department of Dermatology, and the Department of Immunology and Rheuma­tology at Stanford University School of Medicine, Calif. He points out, “Morphea can be a devastating disease for patients for many reasons—the sclerosis, which can lead to loss of joint mobility and functional disability; the cosmetic disfiguration, caused by dyspigmentation or atrophy; pruritus; and pain.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

No available treatments directly address the underlying disease etiology. Topical and systemic steroids are frequently prescribed. “Current therapies include potentially toxic medications, [such as] methotrexate, which are only modestly effective in a subset of patients,” adds Dr. Fiorentino. “Ultraviolet light therapy is another modality, especially UVA1, but unfortunately these treatment units are only available at select sites in the U.S. and are inaccessible for most patients.”

The majority of patients with localized scleroderma first experience symptoms in childhood.3 Dr. Fiorentino notes that pediatric morphea, in particular, represents a major unmet need, because these patients often have more sclerotic disease that can affect joint function and cause significant pain and disability. The linear subtype of localized scleroderma causes morphea lesions on the trunk or extremities that cross over joints. When it affects the epiphyseal growth plate, permanent limb shortening or atrophy can result.3

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Scleroderma Tagged With: FCX‑013, gene therapy, morphea, systemic sclerosis (SSc)Issue: August 2019

You Might Also Like:
  • Targeted Therapy for Scleroderma Fibrosis
  • A Deep-Dive Discussion with the Author of a Systemic Scleroderma Study
  • Studies Show Promise for Scleroderma Therapy and Prediction of Progressing Disease
  • Rehabilitation, Therapy Goals for Scleroderma, Acroosteolysis

About Ruth Jessen Hickman, MD

Ruth Jessen Hickman, MD, was born and raised in eastern Kentucky, where she first cultivated her love of literature, writing and personal narratives. She attended Kenyon college, where she received a Bachelor of Arts in philosophy, summa cum laude. She worked with individuals with psychiatric conditions and later in a neuroscience lab at the University of Illinois, Chicago, before graduating from Indiana University Medical School in 2011. Instead of pursuing clinical medicine, Ruth opted to build on her strength of clearly explaining medical topics though a career as a freelance medical writer, writing both for lay people and for health professionals. She writes across the biomedical sciences, but holds strong interests in rheumatology, neurology, autoimmune diseases, genetics, and the intersection of broader social, cultural and emotional contexts with biomedical topics. Ruth now lives in Bloomington, Ind., with her husband, son and cat. She can be contacted via her website at www.ruthjhickmanmd.com.

View more by this author»

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.